Cytarabine and Droperidol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cytarabine (cytarabine) and Droperidol (droperidol). Common drug interactions include pulmonary oedema among females and cytokine release syndrome among males.

The phase IV clinical study analyzes what interactions people have when they take Cytarabine and Droperidol. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Cytarabine?

Cytarabine has active ingredients of cytarabine. It is often used in acute myelogenous leukemia (aml) - adult. eHealthMe is studying from 65,358 Cytarabine users. Check the latest studies of Cytarabine.

What is Droperidol?

Droperidol has active ingredients of droperidol. eHealthMe is studying from 2,452 Droperidol users. Check the latest studies of Droperidol.

On Jul, 25, 2026

12 people who take Cytarabine and Droperidol together, and have interactions are studied.

Cytarabine and Droperidol drug interactions.

What are the common drug interactions of Cytarabine and Droperidol, by gender? *:

female:

Pulmonary oedema (fluid accumulation in the lungs)
Respiratory failure (inadequate gas exchange by the respiratory system)
Septic shock (shock due to blood infection)
Stenotrophomonas infection
Mucosal inflammation (infection of mucous membrane)
Atelectasis (partial or complete collapse of the lung)
Coagulopathy (blood's ability to clot is impaired)
Gastrointestinal mucosal necrosis (damage of mucous membrane in gastrointestinal tract)
General physical health deterioration (weak health status)
Generalised oedema (swelling all over the body)

male:

Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Enterococcal sepsis
Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
Bacterial sepsis
Bacteroides bacteraemia

What are the common drug interactions of Cytarabine and Droperidol, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Enterococcal sepsis
Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
Bacterial sepsis
Bacteroides bacteraemia

20-29:

n/a

30-39:

Mucosal inflammation (infection of mucous membrane)

40-49:

n/a

50-59:

Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
Delirium (wild excitement)
Coagulopathy (blood's ability to clot is impaired)
Gastrointestinal mucosal necrosis (damage of mucous membrane in gastrointestinal tract)
General physical health deterioration (weak health status)
Generalised oedema (swelling all over the body)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Myelofibrosis (a disease in which abnormal blood cells and fibres build up inside the bone marrow)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Viral infection

60+:

n/a

What are the existing conditions these people have? *

Pain: 10 people, 83.33%
Nausea (feeling of having an urge to vomit): 10 people, 83.33%
Fever: 10 people, 83.33%
Insomnia (sleeplessness): 10 people, 83.33%
Stress And Anxiety: 9 people, 75.00%
Constipation: 9 people, 75.00%
Febrile Neutropenia (fever with reduced white blood cells): 9 people, 75.00%
Generalised Oedema (swelling all over the body): 9 people, 75.00%
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood): 8 people, 66.67%
Sedation: 6 people, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Cytarabine and Droperidol?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously